Gilead Provides Update on U.S. Indication for Trodelvy® in …
3 days ago · Back. Foster City, Calif., October 18, 2024 – Gilead Sciences, Inc. today announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy® (sacituzumab govitecan-hziy; SG) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing ...
Gilead withdraws bladder cancer drug in US after failed trial
2 days ago · GILD. (Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a ...
Gilead withdraws Trodelvy in bladder cancer | BioPharma Dive
3 days ago · Gilead will no longer sell its combination drug Trodelvy to treat bladder cancer, announcing Friday it had agreed with the Food and Drug Administration to withdraw it following negative trial results. The FDA granted Trodelvy accelerated approval for bladder cancer in 2021, based on results that found it shrank tumors in people whose disease ...
Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After …
3 days ago · By Frank Vinluan on October 18, 2024. Gilead Sciences is voluntarily withdrawing cancer drug Trodelvy from the U.S. market as a treatment for advanced cases of urothelial carcinoma, a move that ...
Trodelvy US Indication for Metastatic Urothelial Cancer to Be
3 days ago · Trodelvy, a Trop-2-directed antibody and topoisomerase inhibitor conjugate, had received accelerated approval in 2021 for the treatment of locally advanced or metastatic urothelial cancer (mUC) in ...
Gilead to pull Trodelvy indication (GILD:NASDAQ) - Seeking Alpha
2 days ago · Justin Sullivan/Getty Images News. Gilead (NASDAQ: GILD) on Friday announced plans to voluntarily withdraw a U.S. indication for its antibody-drug conjugate Trodelvy in bladder cancer after a late ...
Gilead's Trodelvy triplet underwhelms, but exec says data bolster ...
Sep 9, 2024 · Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks like that win won’t come from a triplet regimen that combines the...
Gilead to withdraw Trodelvy accelerated approval for bladder …
2 days ago · Gilead Sciences announced its intention to voluntarily withdraw the accelerated approval for sacituzumab govitecan-hziv for treatment of certain patients with advanced bladder cancer.The ...
Gilead's at 'just the beginning' of cell therapy movement: exec
Feb 7, 2024 · Another major drug in Gilead’s oncology franchise is the antibody-drug conjugate (ADC) Trodelvy. That drug saw sales skyrocket by 56% over the full year and is a key driver for the company.
Gilead writes $2.4B off Trodelvy as CEO underscores focus - Fierce …
Apr 26, 2024 · After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on Trodelvy, which serves as the cornerstone of the company’s solid tumor ambition.
- Some results have been removed